Would you consider chemoimmunotherapy (CP-Pembro-AC) in triple negative breast cancer if tumor is not palpable on physical exam?

KN522 regimen is approved for cT2 or greater (tumor >2cm) regardless of nodal involvement or cT1c with nodal involvement. The tumor size can be determined by a physical exam or radiologic assessment or both. Therefore, it is perfectly fine to use KN522 regimen if the tumor is not palpable as long as...